<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02604264</url>
  </required_header>
  <id_info>
    <org_study_id>CLP-0001</org_study_id>
    <nct_id>NCT02604264</nct_id>
  </id_info>
  <brief_title>Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap</brief_title>
  <official_title>Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pursuit Vascular, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fresenius Medical Care North America</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pursuit Vascular, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess positive blood cultures (PBCs) in hemodialysis central venous catheter (CVC)
      patients using two FDA cleared devices: ClearGuard HD end caps compared to conventional end
      caps.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive Blood Cultures (PBCs) Per 1,000 Central Venous Catheter (CVC)-Days</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>This was calculated by dividing the cumulative number of PBCs by cumulative time at-risk as follows.
The National Healthcare Safety Network (NHSN) Center for Disease Control (CDC) 21-day outpatient hemodialysis patient rule is as follows: A PBC is considered a new event and counted only if it occurred 21 days or more after a previously reported PBC in the same patient; new PBC events are based on blood cultures drawn as an outpatient or within one calendar day after a hospital admission. Following a PBC additional same-type events were counted beginning 21 days following the initial event; the CVC-days were counted during this period. The CVC-days were calculated by summing the number of days each patient was at-risk of accruing a PBC. This analysis included all subjects that participated in the study that were not otherwise censored to more accurately count CVC-days.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2912</enrollment>
  <condition>End Stage Renal Disease (ESRD)</condition>
  <arm_group>
    <arm_group_label>ClearGuard HD end cap</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard hemodialysis end cap</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ClearGuard HD end cap</intervention_name>
    <description>The ClearGuard HD End Cap elutes chlorhexidine acetate into the hemodialysis catheter hub</description>
    <arm_group_label>ClearGuard HD end cap</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients dialyzing with a central venous catheter

        Exclusion Criteria:

          -  Known allergy to chlorhexidine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Hymes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fresenius Medical Care North America</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Frenova Renal Research</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pursuitvascular.com</url>
    <description>Pursuit Vascular website</description>
  </link>
  <results_reference>
    <citation>Hymes JL, Mooney A, Van Zandt C, Lynch L, Ziebol R, Killion D. Dialysis Catheter-Related Bloodstream Infections: A Cluster-Randomized Trial of the ClearGuard HD Antimicrobial Barrier Cap. Am J Kidney Dis. 2017 Feb;69(2):220-227. doi: 10.1053/j.ajkd.2016.09.014. Epub 2016 Nov 10.</citation>
    <PMID>27839894</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>November 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <results_first_submitted>March 21, 2017</results_first_submitted>
  <results_first_submitted_qc>March 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2017</results_first_posted>
  <last_update_submitted>August 13, 2018</last_update_submitted>
  <last_update_submitted_qc>August 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>ClearGuard HD end cap: The ClearGuard HD End Cap elutes chlorhexidine acetate into the hemodialysis catheter hub</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Standard hemodialysis end cap</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Run-In</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="618"/>
                <participants group_id="P2" count="611">The 1-mo run-in period data was used to determine pre-study demographics and PBC rate.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="618"/>
                <participants group_id="P2" count="611"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1445"/>
                <participants group_id="P2" count="1467"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1245"/>
                <participants group_id="P2" count="1225"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="242"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Didn't use CVC for at least 21 days</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="242"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This is the intervention population data. The baseline data came from the 1 month run-in period prior to the start of the intervention period and is referred to as the run-in rather than baseline period. The run-in data was used to determine pre-study demographics and PBC rate.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>ClearGuard HD end cap: The ClearGuard HD End Cap elutes chlorhexidine acetate into the hemodialysis catheter hub</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Standard hemodialysis end cap</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1245"/>
            <count group_id="B2" value="1225"/>
            <count group_id="B3" value="2470"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.5" spread="15.1"/>
                    <measurement group_id="B2" value="60.6" spread="15.1"/>
                    <measurement group_id="B3" value="61.1" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="591"/>
                    <measurement group_id="B2" value="559"/>
                    <measurement group_id="B3" value="1150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="654"/>
                    <measurement group_id="B2" value="666"/>
                    <measurement group_id="B3" value="1320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="566"/>
                    <measurement group_id="B2" value="495"/>
                    <measurement group_id="B3" value="1061"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="609"/>
                    <measurement group_id="B2" value="631"/>
                    <measurement group_id="B3" value="1240"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1245"/>
                    <measurement group_id="B2" value="1225"/>
                    <measurement group_id="B3" value="2470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Positive Blood Cultures (PBCs) Per 1,000 Central Venous Catheter (CVC)-Days</title>
        <description>This was calculated by dividing the cumulative number of PBCs by cumulative time at-risk as follows.
The National Healthcare Safety Network (NHSN) Center for Disease Control (CDC) 21-day outpatient hemodialysis patient rule is as follows: A PBC is considered a new event and counted only if it occurred 21 days or more after a previously reported PBC in the same patient; new PBC events are based on blood cultures drawn as an outpatient or within one calendar day after a hospital admission. Following a PBC additional same-type events were counted beginning 21 days following the initial event; the CVC-days were counted during this period. The CVC-days were calculated by summing the number of days each patient was at-risk of accruing a PBC. This analysis included all subjects that participated in the study that were not otherwise censored to more accurately count CVC-days.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ClearGuard HD end cap: The ClearGuard HD End Cap elutes chlorhexidine acetate into the hemodialysis catheter hub</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard hemodialysis end cap</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Blood Cultures (PBCs) Per 1,000 Central Venous Catheter (CVC)-Days</title>
          <description>This was calculated by dividing the cumulative number of PBCs by cumulative time at-risk as follows.
The National Healthcare Safety Network (NHSN) Center for Disease Control (CDC) 21-day outpatient hemodialysis patient rule is as follows: A PBC is considered a new event and counted only if it occurred 21 days or more after a previously reported PBC in the same patient; new PBC events are based on blood cultures drawn as an outpatient or within one calendar day after a hospital admission. Following a PBC additional same-type events were counted beginning 21 days following the initial event; the CVC-days were counted during this period. The CVC-days were calculated by summing the number of days each patient was at-risk of accruing a PBC. This analysis included all subjects that participated in the study that were not otherwise censored to more accurately count CVC-days.</description>
          <units>PBCs per 1,000 CVC-days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1245"/>
                <count group_id="O2" value="1225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26"/>
                    <measurement group_id="O2" value="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>The run-in data was used to determine pre-study demographics and PBC rate so no adverse event analysis was performed for the this period. This was a pragmatic post market study. There was an informed consent waiver and there were no study case report forms (CRF's). Treatment arm adverse events were monitored during the 12-month intervention period using the FDA Manufacturer and User Facility Device Experience (MAUDE) database and none were reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>ClearGuard HD end cap: The ClearGuard HD End Cap elutes chlorhexidine acetate into the hemodialysis catheter hub</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Standard hemodialysis end cap</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="1245"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="1225"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1225"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1225"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a pragmatic post market study. There was an informed consent waiver and no CRF's. Treatment arm adverse events during the 12-month intervention period were monitored using the FDA MAUDE database and none were reported.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jeffrey L. Hymes, MD</name_or_title>
      <organization>Fresenius Medical Care North America</organization>
      <phone>615-567-4821</phone>
      <email>Jeffrey.HymesMD@fmc-na.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

